ReviewInternational journal of ophthalmology2017
The omega-3 and retinopathy of prematurity relationship.
Review in International journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07652684 (Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants: A Randomized Controlled Trial (The PRELUDE Trial)
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Omega-3 Long Chain Polyunsaturated Fatty Acid Supplementation for Prevention of Retinopathy of Prematurity in Pre-Term Low Birth Weight Infants: A Pilot Study.Health science reports · 2025Article
- Evaluation of the Effects of Lipoxin A4 and Resolvin D1 on the Severity of Transient Tachypnea of the Newborn: A Prospective Study.Children (Basel, Switzerland) · 2025Article
- Association of fish oil containing lipid emulsions with retinopathy of prematurity: a retrospective observational study.BMC pediatrics · 2022Observational
- Effect of Probenecid on Endothelial Cell Growth Rate and Retinal Angiogenesis in an Oxygen-Induced Retinopathy Model.Frontiers in pharmacology · 2021Article
- Oxidative Stress Markers and the Retinopathy of Prematurity.Journal of clinical medicine · 2020Review
- Plasma Oxidative Status in Preterm Infants Receiving LCPUFA Supplementation: A Pilot Study.Nutrients · 2020Article
- Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future.Frontiers in pharmacology · 2019Article
- Bioactive lipids and pathological retinal angiogenesis.British journal of pharmacology · 2019Review
- The role of specialized pro-resolving mediators in maternal-fetal health.Prostaglandins, leukotrienes, and essential fatty acids · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this article is to examine the effect of omega-3 (ω-3) long-chain polyunsaturated fatty acids (LCPUFAs) intake on retinopathy of prematurity (ROP) by reviewing the experimental and clinical trials conducted on animal models and infants. LCPUFAs demonstrate cytoprotective and cytotherapeutic actions contributing to a number of anti-angiogenic and neuroprotective mechanisms within the retina. Their intake appears to have a beneficial effect on ischemia, oxidative stress, inflammation and cellular signaling mechanisms, influencing retinal cell gene expression and cellular differentiation. ω-3 LCPUFAs may modulate metabolic processes that activate molecules implicated in the pathogenesis of vasoproliferative and neurodegenerative retinal diseases such as ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.